Literature DB >> 27904669

Astragaloside IV enhances cardioprotection of remote ischemic conditioning after acute myocardial infarction in rats.

Songyi Cheng1, Peng Yu2, Li Yang1, Haibo Shi2, Anxia He3, Hanyu Chen1, Jie Han1, Liang Xie4, Jiandong Chen2, Xiaohu Chen2.   

Abstract

BACKGROUND: Remote ischemic conditioning (RIC) has been shown to be a practical method for protecting the heart from ischemic/reperfusion (I/R) injury. In the present study, we investigated whether or not the combination of RIC and Astragaloside IV (AS-IV) could improve cardioprotection against acute myocardial infarction (AMI)-induced heart failure (HF) when compared with individual treatments.
MATERIAL AND METHODS: A rat model of AMI was established via permanent ligation of the left anterior descending coronary artery (LAD). Postoperatively, the rats were randomly grouped into a sham group (n=10), a model group (n=15), an AS-IV alone group (n=15), an RIC alone group (n=15) and a combined treatment group (AS-IV+RIC; n=15). All treatments were administered for 2 weeks.
RESULTS: After treatment for 2 weeks, the survival rate was improved, the cardiac function was preserved and the infarcted size was limited in AS-IV alone and RIC alone treatment groups compared to the model group, whereas the combined treatment yielded the most optimal protective effects. Additional studies suggested that AS-IV enhanced the cardioprotective effects of RIC by alleviating myocardial fibrosis, suppressing inflammation, attenuating apoptosis and ameliorating impairment of the myocardial ultrastructural.
CONCLUSION: AS-IV enhances the cardioprotective effects of RIC against AMI-induced HF and ventricular remodeling, which represents a potential therapeutic approach for preserving cardiac function and improving the prognosis of AMI.

Entities:  

Keywords:  Astragaloside IV; acute myocardial infarction; cardioprotection; remote ischemic conditioning; ventricular remodeling

Year:  2016        PMID: 27904669      PMCID: PMC5126311     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  48 in total

Review 1.  Another way to die: autophagic programmed cell death.

Authors:  Y Tsujimoto; S Shimizu
Journal:  Cell Death Differ       Date:  2005-11       Impact factor: 15.828

Review 2.  Programmed necrosis, not apoptosis, in the heart.

Authors:  Gloria Kung; Klitos Konstantinidis; Richard N Kitsis
Journal:  Circ Res       Date:  2011-04-15       Impact factor: 17.367

3.  Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning.

Authors:  M R Schmidt; M Smerup; I E Konstantinov; M Shimizu; J Li; M Cheung; P A White; S B Kristiansen; K Sorensen; V Dzavik; A N Redington; R K Kharbanda
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-12-15       Impact factor: 4.733

4.  Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs.

Authors:  Juan José Alburquerque-Béjar; Ignasi Barba; Javier Inserte; Elisabet Miró-Casas; Marisol Ruiz-Meana; Marcos Poncelas; Úrsula Vilardosa; Laura Valls-Lacalle; Antonio Rodríguez-Sinovas; David Garcia-Dorado
Journal:  Cardiovasc Res       Date:  2015-06-04       Impact factor: 10.787

5.  Astragaloside IV protects heart from ischemia and reperfusion injury via energy regulation mechanisms.

Authors:  Lei Tu; Chun-Shui Pan; Xiao-Hong Wei; Li Yan; Yu-Ying Liu; Jing-Yu Fan; Hong-Na Mu; Quan Li; Lin Li; Yu Zhang; Ke He; Xiao-Wei Mao; Kai Sun; Chuan-She Wang; Chang-Cheng Yin; Jing-Yan Han
Journal:  Microcirculation       Date:  2013-11       Impact factor: 2.628

6.  Astragaloside IV and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium.

Authors:  Yan Zhao; Qiang Li; Wenjun Zhao; Jia Li; Yan Sun; Kang Liu; Baolin Liu; Ning Zhang
Journal:  J Ethnopharmacol       Date:  2015-04-25       Impact factor: 4.360

7.  Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning.

Authors:  Ping Xin; Wei Zhu; Jing Li; Shixin Ma; Lixing Wang; Mingya Liu; Jingbo Li; Meng Wei; Andrew N Redington
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-05       Impact factor: 4.733

8.  Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction.

Authors:  Meng Wei; Ping Xin; Shuai Li; Jianping Tao; Yapeng Li; Jing Li; Mingya Liu; Jingbo Li; Wei Zhu; Andrew N Redington
Journal:  Circ Res       Date:  2011-04-07       Impact factor: 17.367

9.  Astragaloside IV prevents lipopolysaccharide-induced injury in H9C2 cardiomyocytes.

Authors:  Shi-Guang Wang; Yan Xu; Hao Xie; Wei Wang; Xiao-Hu Chen
Journal:  Chin J Nat Med       Date:  2015-02

Review 10.  The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction.

Authors:  Samantha D Francis Stuart; Nicole M De Jesus; Merry L Lindsey; Crystal M Ripplinger
Journal:  J Mol Cell Cardiol       Date:  2015-12-29       Impact factor: 5.000

View more
  7 in total

1.  Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway.

Authors:  Xiaoqing Zhang; Huiyan Qu; Tao Yang; Qian Liu; Hua Zhou
Journal:  Cell Cycle       Date:  2022-06-30       Impact factor: 5.173

2.  In vivo effects of nitrosyl hydrogen on cardiac function and sarcoplasmic reticulum calcium pump (SERCA2a) in rats with heart failure after myocardial infarction.

Authors:  Yanqing Guo; Jiyao Xu; Yongzhi Deng; Li Wu; Jingping Wang; Jian An
Journal:  Cardiovasc Diagn Ther       Date:  2020-12

3.  A critical courier role of volatile oils from Dalbergia odorifera for cardiac protection in vivo by QiShenYiQi.

Authors:  Jiahui Yu; Wen Zhang; Yiqian Zhang; Yadong Wang; Boli Zhang; Guanwei Fan; Yan Zhu
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

4.  Astragaloside IV protects cardiomyocytes against hypoxia injury via HIF-1α and the JAK2/STAT3 pathway.

Authors:  Bei Li; Junjian Yu; Peipei Liu; Taohui Zeng; Xueliang Zeng
Journal:  Ann Transl Med       Date:  2021-09

5.  Inhibition of miRNA-1-Mediated Inflammation and Autophagy by Astragaloside IV Improves Lipopolysaccharide-Induced Cardiac Dysfunction in Rats.

Authors:  Qiuning Wang; Weiying Chen; Xuefeng Yang; Ying Song; Xiaowei Sun; Guizhou Tao; Hong Wang; Nan Zhao; Yue Huang; Erqing Chai; Futian Tang
Journal:  J Inflamm Res       Date:  2022-04-23

Review 6.  Anti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic.

Authors:  Ping Liu; Haiping Zhao; Yumin Luo
Journal:  Aging Dis       Date:  2017-12-01       Impact factor: 6.745

7.  A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury.

Authors:  Qun Zheng; Jia-Zhen Zhu; Xiao-Yi Bao; Peng-Chong Zhu; Qiang Tong; Yue-Yue Huang; Qi-Hao Zhang; Ke-Jian Zhang; Guo-Qing Zheng; Yan Wang
Journal:  Front Physiol       Date:  2018-07-03       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.